8-K: Marpai Secures $350K in Private Placement Offering

Marpai Inc. announced a private placement of common stock and warrants, raising approximately $350,000 for working capital and general corporate purposes.

Summary

• Marpai Inc. entered into a Securities Purchase Agreement on December 22, 2025, with certain investors.
• The company agreed to issue and sell 350,000 shares of its Class A common stock and warrants to purchase up to 700,000 shares of Common Stock in a private placement.
• The purchase price for each share of Common Stock and accompanying Common Warrant is $1.00.
• The Common Warrants have an exercise price of $1.00 per share, are exercisable immediately, and will be exercisable for three years following the date of issuance.
• The gross proceeds to the company from the offering are expected to be approximately $350,000.
• The company intends to use the proceeds from the offering for working capital and general corporate purposes.
• The offering is expected to close on or about December 22, 2025, subject to customary closing conditions.
• The securities issued are exempt from registration requirements of the Securities Act of 1933 pursuant to Section 4(a)(2) and/or Rule 506(b) of Regulation D.
• Purchasers were granted the right for six months to include their Common Shares and Common Warrant Shares in any other registration of securities filed by the company (with exceptions).

Sentiment

Score: 6

Explanation: The company successfully secured capital for working capital and general corporate purposes, which is a positive for ongoing operations. However, the relatively small amount raised and the associated dilution from both shares and warrants temper the overall positive sentiment, suggesting a necessary rather than highly advantageous funding event.

Positives

• Successfully secured approximately $350,000 in gross proceeds, providing additional working capital for the company.
• The private placement structure, including warrants, offers potential for future capital infusion if warrants are exercised.
• The company was able to raise capital from investors without undergoing a full public registration process.

Negatives

• The issuance of 350,000 shares of common stock and warrants for up to 700,000 shares will result in dilution for existing shareholders.
• The relatively small amount of capital raised ($350,000) might indicate limited access to larger funding sources or specific, immediate funding needs.
• The warrant exercise price of $1.00 per share, matching the purchase price of the common stock, suggests the current market valuation may be at or below this level.

Risks

• Existing shareholders will experience dilution from the issuance of 350,000 new shares and potential future dilution from the exercise of up to 700,000 warrants.
• If the company's stock price does not rise above the $1.00 warrant exercise price, the warrants may not be exercised, limiting the potential for additional capital from this source.
• The closing of the offering is subject to customary conditions, including no material adverse effect on the company or general market conditions, which could prevent or delay the funding.
• The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption, potentially limiting liquidity for the private placement investors.

Future Outlook

The company intends to use the proceeds from this offering for working capital and general corporate purposes, indicating a focus on maintaining operational liquidity and supporting ongoing business activities. The warrants provide a potential future source of capital if exercised by investors.

Management Comments

• The report was signed on behalf of Marpai, Inc. by Damien Lamendola, Chief Executive Officer.

Industry Context

This private placement represents a common strategy for smaller public companies, particularly those listed on OTC markets, to raise capital efficiently from accredited investors. Such offerings often address immediate funding needs for operations, growth initiatives, or to strengthen the balance sheet without the extensive regulatory requirements and costs associated with a fully registered public offering.

Comparison to Industry Standards

• Private placements are a standard capital-raising mechanism for companies, especially those on alternative trading markets like OTCQX, which may have less access to broader public equity markets compared to larger exchanges.
• The inclusion of warrants as a 'sweetener' alongside common stock is a common practice in private placements to attract investors by offering additional upside potential.
• The provision of 'piggy-back' registration rights to investors is also a standard feature, providing a pathway for these private placement investors to achieve liquidity for their restricted shares in the future.

Legal Proceedings

• To the company's knowledge, there are no material actions, suits, inquiries, notices of violation, proceedings, or investigations pending or threatened against or affecting the company or its properties, except as disclosed in SEC reports.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new common stock and potential future dilution from warrant exercises.
• Company Operations: The capital infusion provides essential working capital, supporting the company's operational stability and ability to pursue general corporate purposes.
• Investors (Purchasers): The investors gain equity ownership and potential future upside through the warrants, along with 'piggy-back' registration rights to facilitate liquidity for their investment.

Next Steps

• The closing of the offering is expected on or about December 22, 2025, subject to the satisfaction of customary closing conditions.
• The company will utilize the proceeds for working capital and general corporate purposes.
• Investors may exercise their warrants to purchase additional shares over the next three years.
• Purchasers have the right for six months to include their shares and warrant shares in any future registration statement filed by the company.

Key Dates

Recommendation

The capital raise provides necessary funding for working capital, which is a positive for the company's operational stability. However, the dilution from the issuance of new shares and warrants, coupled with the relatively small amount raised, suggests that while the company is addressing its funding needs, it may still face challenges or require further capital in the future. Investors should hold and monitor the company's use of proceeds and future performance.

Keywords

Marpai Inc., MRAI, Private Placement, Securities Purchase Agreement, Common Stock, Warrants, Capital Raise, Working Capital, Dilution, SEC Filing, Form 8-K, OTCQX Market